NAFDAC (Nigeria)

NAFDAC (National Agency for Food and Drug Administration and Control) is Nigeria's federal regulatory authority responsible for regulating + controlling the manufacture, importation, exportation, distribution, advertisement, sale + use of food, drugs, cosmetics, medical devices, chemicals + packaged water in Nigeria. NAFDAC was established by Decree 15 of 1993 — promulgated under the military government of General Ibrahim Babangida in response to widespread fake-drug + adulterated-food crises of the late 1980s + early 1990s that killed thousands of Nigerians + undermined public confidence in medicines + food. The agency commenced operations 1 January 1994 + is now codified as the NAFDAC Act, Cap N1, Laws of the Federation of Nigeria 2004 with subsequent amendments. NAFDAC's headquarters is in Abuja + the agency operates laboratory complexes in Lagos (Yaba Central Laboratory + Oshodi), Kaduna + Port Harcourt + has six geo-political zonal offices (North-West / North-East / North-Central / South-West / South-East / South-South) + 36 state offices + the FCT office.

NAFDAC's organisational structure includes:

• Director-General (DG) — chief executive appointed by the President of the Federal Republic of Nigeria; reports to the Honourable Minister of Health + Social Welfare; serves a fixed term renewable once.
• Directorate of Drug Evaluation + Research (DER) — drug registration, generics, biosimilars, vaccines, biologicals, herbal medicines, nutraceuticals.
• Directorate of Food Safety + Applied Nutrition (FSAN) — food registration, packaged water, food fortification, food labelling, allergens.
• Directorate of Veterinary Medicines + Allied Products (VMAP) — veterinary medicines, animal feed additives, biologicals.
• Directorate of Cosmetics + Medical Devices (C&MD) — cosmetics + medical-device registration + post-market surveillance.
• Directorate of Chemical Evaluation + Research (CER) — chemical + agro-chemical + pesticide registration.
• Directorate of Pharmacovigilance + Post-Market Surveillance (PV/PMS) — adverse-drug-reaction reporting + post-market surveillance + risk communication.
• Directorate of Investigation + Enforcement (I&E) — anti-counterfeit operations + enforcement of NAFDAC Act + Counterfeit Act.
• Directorate of Laboratory Services — Yaba Central Laboratory + Oshodi Laboratory + Kaduna Laboratory + Port Harcourt Laboratory; quality-control testing + regulatory laboratory analysis.
• Directorate of Ports Inspection — port-of-entry inspection at Lagos seaports + Kano + Lagos international airports + land borders.
• Directorate of Establishment Inspection — GMP inspection of domestic + foreign manufacturing facilities.
• Directorate of Regulatory Affairs — regulations drafting + international engagement + legal affairs.

NAFDAC's regulatory portfolio is substantially broader than most peer NMRAs — covering food + drugs + medicines + cosmetics + chemicals + medical devices + packaged water + nutraceuticals + veterinary products under a single agency. This reflects the Nigerian model that consolidates the FDA-equivalent + USDA-equivalent + EPA-equivalent functions into one federal authority. NAFDAC is distinct from + complementary to: the Pharmacists Council of Nigeria (PCN, which regulates pharmacy practice + pharmacist registration + pharmaceutical premises licensing); the Medical + Dental Council of Nigeria (MDCN, which regulates medical practice); the National Primary Health Care Development Agency (NPHCDA, responsible for immunisation programmes); the Federal Ministry of Agriculture (which regulates primary agricultural production); + the Standards Organisation of Nigeria (SON, which sets non-health-related industrial standards).

Legal foundations are the NAFDAC Act (Cap N1 LFN 2004, originally Decree 15 of 1993), the Counterfeit + Fake Drugs + Unwholesome Processed Foods (Miscellaneous Provisions) Act (Cap C34 LFN 2004, originally Decree 21 of 1988 + Decree 25 of 1999), the Food + Drugs Act (Cap F32 LFN 2004), the NAFDAC Drug + Related Products Registration Regulations 2021, the NAFDAC Good Manufacturing Practice Regulations 2021 + a substantial body of NAFDAC regulations + guidelines implementing the federal framework.

NAFDAC achieved WHO Maturity Level 3 (ML3) for vaccines in November 2022 — making Nigeria the first country in the WHO Africa Region to achieve ML3 for vaccines + positioning NAFDAC as a regional reference regulator within the AU African Medicines Agency (AMA) framework + the AUDA-NEPAD AMRH framework. NAFDAC has applied for PIC/S Membership + is an active participant in WHO PQ Collaborative Registration Procedure (CRP), ECOWAS-MRH, AMRH + ICDRA.

Nigerian pharmaceutical regulation operates under a layered framework of primary legislation, NAFDAC regulations + NAFDAC guidelines:

• NAFDAC Act (Cap N1 LFN 2004) — establishes NAFDAC + its functions, powers + governance; provides for ministerial direction + Director-General appointment + Council of NAFDAC.
• Counterfeit + Fake Drugs + Unwholesome Processed Foods (Miscellaneous Provisions) Act (Cap C34 LFN 2004) — criminalises manufacture, importation, distribution + sale of counterfeit + fake drugs + unwholesome processed foods; substantial criminal penalties including up to 15 years imprisonment.
• Food + Drugs Act (Cap F32 LFN 2004) — older legislation now substantially superseded by NAFDAC Act + Counterfeit Act but providing residual framework.
• Pharmacy + Therapeutics Act (Cap P17 LFN 2004) — regulates pharmacy practice + pharmacist registration; administered by Pharmacists Council of Nigeria (PCN) rather than NAFDAC.
• NAFDAC Drug + Related Products Registration Regulations 2021 — current registration framework for medicines + biologicals + biosimilars + vaccines + herbal medicines + nutraceuticals.
• NAFDAC Good Manufacturing Practice Regulations 2021 — current Nigerian GMP regulations substantively aligned with WHO TRS 986 Annex 2 + ICH Q7 + EU GMP; mandatory for Nigerian + foreign manufacturers exporting to Nigeria.
• NAFDAC Good Clinical Practice Guidelines — substantively aligned with ICH E6(R2) GCP; mandatory for clinical trials conducted in Nigeria.
• NAFDAC Good Distribution Practice Regulations — substantively aligned with WHO + EU GDP.
• NAFDAC Pharmacovigilance Guidelines — substantively aligned with WHO + EU GVP Modules; Nigerian-specific reporting via NAFDAC Med-Safety + NPC platforms.
• NAFDAC Medical Devices Registration Regulations — risk-based classification + ISO 13485 recognition + Nigerian-specific overlay.
• NAFDAC Cosmetic Products Regulations — registration + labelling + safety substantiation for cosmetics circulating in Nigeria.
• NAFDAC Food Registration + Labelling Regulations — food + packaged water + nutraceutical registration + Nigerian-language + Nigerian-specific labelling.
• NAFDAC Variations Regulations — Type IA / IB / II variations procedure substantively similar to WHO + EU + ECOWAS-MRH variations framework.
• NAFDAC Advertising + Promotion Regulations — pre-approval of medicines + medical-device + food advertising + promotional materials.
• NAFDAC Mobile Authentication Service (MAS) Regulations — mandatory anti-counterfeit scratch-code verification for selected high-risk medicines.

NAFDAC's Mobile Authentication Service (MAS) is Nigeria's flagship anti-counterfeit medicine programme. Launched in 2010 + substantially expanded through 2015 + 2020, MAS provides a unique-scratch-code verification system that allows consumers + healthcare professionals to verify medicine authenticity at point of dispensing using SMS or mobile-app verification. MAS was a direct response to Nigeria's chronic counterfeit-medicine crisis + remains one of Africa's most established + most studied anti-counterfeit programmes.

• Established 2010 + mandated for selected high-risk medicines including antimalarials (artemisinin-based combination therapies / ACTs), antiretrovirals (ARVs) for HIV + selected antibiotics + maternal health medicines.
• Unique-scratch-code verification — every pack of MAS-registered medicines bears a unique 12-digit scratch code under a removable panel; consumer scratches code + sends free SMS to NAFDAC short codes (38353, 38673 + others) or uses NAFDAC mobile app to verify authenticity.
• Real-time response — NAFDAC backend returns SMS response confirming: GENUINE (with brand + manufacturer + expiry verification) or SUSPECTED COUNTERFEIT (with NAFDAC investigation alert).
• Free SMS verification — verification is free to consumers across all Nigerian mobile networks (MTN, Glo, Airtel, 9mobile); NAFDAC bears the SMS cost as a public-health investment.
• Counterfeit-flagging — every suspect verification triggers NAFDAC alert + investigation; supply-chain forensics trace counterfeit batches to source pharmacy / wholesaler / importer for enforcement under Counterfeit Act.
• Successor frameworks — MAS has been studied + emulated by other African + Asian regulators including Ghana FDA + Tanzanian TMDA; substantially preceded EU FMD + Saudi GHAD + Russia Chestny ZNAK in concept though with simpler verification mechanism.
• Future evolution — NAFDAC has indicated intention to evolve MAS toward GS1-aligned 2D Data Matrix + EPCIS-aligned full track-and-trace (substantively similar to US DSCSA + EU FMD + Russia Chestny ZNAK + Saudi GHAD); transition planning is active but full deployment phase + timeline depends on supply-chain readiness + cross-stakeholder coordination.
• Regional influence — MAS + NAFDAC's anti-counterfeit experience has substantially influenced ECOWAS-MRH + AMRH anti-counterfeit framework development.

NAFDAC medical-device + cosmetic regulation operates under the NAFDAC Medical Devices Registration Regulations + NAFDAC Cosmetic Products Regulations. Foreign manufacturers must appoint a Nigerian Authorised Representative (NAR).

• Risk-based Classification (Class I / II / III / IV + IVD Class I-D) — substantively aligned with GHTF / IMDRF + EU MDR / IVDR with Nigerian-specific overlay.
• Registration Certificate — issued by NAFDAC C&MD Directorate based on technical-file review + Nigerian Authorised Representative designation + Nigerian-language labelling.
• Nigerian Authorised Representative (NAR) — Nigerian-resident legal entity required for foreign manufacturers; bears post-market surveillance responsibility + Nigerian regulatory interface.
• ISO 13485:2016 — recognised by NAFDAC as QMS evidence framework; Nigerian-specific overlay required including Nigerian quality records + Nigerian Authorised Representative QMS interface.
• MDSAP — Nigeria is not currently an MDSAP Participating Regulator + does not accept MDSAP audit reports as direct QMS evidence; ISO 13485 + Nigerian-specific overlay required.
• Reliance pathways — NAFDAC accepts CE Mark + FDA 510(k) + Health Canada + TGA + Swissmedic + MFDS + Japan-approval evidence as supporting evidence under reliance framework; reliance reduces dossier requirements + accelerates review.
• Post-market Surveillance + Materiovigilance — NAFDAC operates medical-device adverse-event reporting; reporting timelines substantively aligned with IMDRF Adverse Event Reporting Codes.
• Cosmetic Notification — cosmetics under NAFDAC Cosmetic Products Regulations require registration + Nigerian-specific labelling; INCI-aligned ingredient listing + safety substantiation.
• Nigerian UDI — NAFDAC has not implemented full UDI equivalent to FDA UDI or EU EUDAMED UDI; Nigerian-specific labelling + product-identification requirements apply.
• Importation Permit — NAFDAC Importation Permit required in addition to registration for foreign-manufactured devices entering Nigeria.

NAFDAC achieved WHO Maturity Level 3 (ML3) for vaccines in November 2022 — making Nigeria the first country in the WHO Africa Region to achieve ML3 for vaccines. This is a substantial regulatory milestone with implications across the African continent.

• WHO Global Benchmarking Tool (GBT) — WHO assessment framework for NRA maturity across nine regulatory functions (RS, MA, VL, LT, CT, RI, MC, LR, MA-PMS); Maturity Level 1 (existence of regulatory framework) through Maturity Level 4 (continuous improvement + advanced reliance).
• Maturity Level 3 (Stable, Well-Functioning + Integrated) — represents WHO's threshold for designating an NRA as a Reference Authority capable of conducting full scientific review + GMP inspection + lot release with international acceptability.
• NAFDAC ML3 for vaccines (November 2022) — first WHO Africa Region NRA to achieve ML3 for vaccines; achieved through multi-year institutional development with WHO + AUDA-NEPAD + Gates Foundation + Gavi support; positions NAFDAC as a vaccine NRA reference within the African Medicines Agency framework.
• African Medicines Agency (AMA) — AU initiative to create a continental medicines agency (substantively similar to EMA for the EU); AMA Treaty entered into force November 2021; NAFDAC ML3 status positions Nigeria as a leading AMA Member State.
• AUDA-NEPAD AMRH (African Medicines Regulatory Harmonisation) — AU programme advancing regulatory harmonisation across African Regional Economic Communities (RECs); NAFDAC is a leading AMRH participant + ECOWAS-MRH Reference Authority.
• ECOWAS-MRH (ECOWAS Medicines Regulatory Harmonisation) — West African Health Organisation (WAHO)-led programme harmonising medicines regulation across 15 ECOWAS Member States; NAFDAC is the most mature ECOWAS NRA + leads ECOWAS-MRH joint assessment + reliance procedures.
• ML4 ambition — NAFDAC has indicated intention to pursue WHO Maturity Level 4 (Continuous Improvement + Advanced Reliance) for vaccines + medicines + ML3 for medicines as next milestones.
• ML3-driven CRP eligibility — NAFDAC ML3 for vaccines enables full participation in WHO CRP (Collaborative Registration Procedure) as both CRP Recipient + potential CRP Reference Authority for African Region products.

• WHO Maturity Level 3 for Vaccines (November 2022) — first WHO Africa Region NRA to achieve ML3 for vaccines; positions NAFDAC as Africa-region vaccine NRA reference.
• WHO PQ Collaborative Registration Procedure (CRP) — active WHO PQ CRP Recipient with substantial use of CRP for vaccines + HIV + malaria + tuberculosis medicines; CRP integration substantially reduces dossier burden + accelerates Nigerian registration.
• AUDA-NEPAD AMRH — leading participant in African Medicines Regulatory Harmonisation programme; co-led ECOWAS-MRH work-stream + AU AMA Treaty implementation.
• ECOWAS-MRH (West African Health Organisation / WAHO) — NAFDAC is the most mature ECOWAS NRA + leads ECOWAS-MRH joint assessment procedure for medicines + vaccines across 15 ECOWAS Member States (Nigeria + Ghana + Côte d'Ivoire + Senegal + Mali + Burkina Faso + Niger + Benin + Togo + Sierra Leone + Liberia + Guinea + Guinea-Bissau + The Gambia + Cape Verde).
• African Medicines Agency (AMA) — AU continental medicines agency under AMA Treaty (entered into force November 2021); NAFDAC is a leading AMA Member State + Nigeria has hosted senior AMA Secretariat positions.
• PIC/S Application — NAFDAC has applied for PIC/S Membership; Nigerian GMP Regulations 2021 + NAFDAC inspectorate practices substantively aligned with PIC/S GMP Guide + Annexes.
• ICDRA Member — active International Conference of Drug Regulatory Authorities participant; hosts ICDRA-related Africa-Region preparatory meetings.
• ICH Observer — NAFDAC is an ICH Observer; ICH guidelines extensively referenced in Nigerian regulatory practice.
• Bilateral MoUs — NAFDAC holds MoUs with FDA + EMA + MHRA + Health Canada + TGA + ANVISA + NMPA + MFDS + Egyptian EDA + South African SAHPRA + Kenyan PPB + Ghanaian FDA + Tanzanian TMDA + Ugandan NDA + Rwandan FDA + many other African regulators.
• WAHO Regional Centre of Regulatory Excellence — University of Ibadan (Nigeria) hosts the WAHO Regional Centre of Regulatory Excellence (RCORE) providing regulatory science capacity-building across West African NRAs.
• Gavi / Global Fund / Gates Foundation cooperation — NAFDAC works closely with Gavi (vaccine procurement), Global Fund (HIV / TB / malaria procurement) + Gates Foundation (regulatory strengthening) on regulatory + supply-chain coordination.
• BRICS + Africa regulatory cooperation — NAFDAC engages BRICS regulators (NMPA, ANVISA, CDSCO, SAHPRA) on regulatory cooperation + reliance.

• Nigerian Authorised Representative or local Sponsor not properly designated — application rejected at NAFDAC intake or post-approval compliance failure.
• Nigerian-specific labelling deficiencies — Nigerian English + culturally appropriate + Nigerian-Naira pricing-reference + Nigerian PIL + storage-condition Nigerian-climate appropriateness.
• GMP Regulations 2021 gaps — applicants assuming EU GMP / PIC/S GMP compliance is sufficient without addressing Nigerian-specific NAFDAC GMP Regulations 2021 + NAFDAC-specific clarifications.
• Nigerian climate-zone stability data missing — Nigerian Climate Zone IVb (hot + very humid) stability data required for medicines + biologicals; many EU-only + US-only stability packages insufficient.
• WHO PQ CRP eligibility not leveraged — WHO-PQ-approved products eligible for accelerated CRP review at NAFDAC; missed opportunity for substantial review time + cost reduction.
• ECOWAS-MRH reliance not leveraged — ECOWAS-MRH joint assessment + reliance pathway underutilised by applicants targeting multiple West African markets.
• MAS scratch-code integration not planned — MAS-mandatory product categories (ACTs + ARVs + selected antibiotics + maternal health medicines) require scratch-code integration; missed integration prevents market entry.
• Variations strategy not planned — Type IA / IB / II variations procedure substantively similar to WHO but with Nigerian-specific timelines + fee structure.
• Renewal timing missed — 5-year renewal must be filed within prescribed window before expiry; missed deadline triggers de-registration + market withdrawal.
• Importation Permit not obtained — NAFDAC Importation Permit required in addition to registration for foreign-manufactured medicines + devices entering Nigeria.
• Port-of-entry inspection gaps — NAFDAC Ports Directorate inspection at Lagos seaports + Kano + Lagos airports + land borders; importer logistics planning must account for inspection clearance time.
• Pharmacovigilance reporting gaps — NAFDAC Med-Safety + NPC reporting requirements substantively similar to WHO GVP + EU GVP but with Nigerian-language + Nigerian-specific format requirements + Nigerian-population pharmacovigilance focus.
• Cosmetics + nutraceutical scope misjudged — NAFDAC's broad single-agency mandate means cosmetics + nutraceuticals require active NAFDAC registration that some sponsors mistakenly assume is exempt.
• Advertising + Promotion pre-approval missed — NAFDAC advertising regulations require pre-approval of medicines + medical-device + food advertising + promotional materials; non-pre-approved materials face enforcement action.
• Counterfeit Act exposure underestimated — Counterfeit + Fake Drugs Act criminal penalties (up to 15 years imprisonment) substantial; Nigerian Authorised Representative + Nigerian directors face personal criminal liability for counterfeit-related findings.

V5 Ultimate provides the operational infrastructure Nigerian + foreign-supplier sites need for NAFDAC Act + NAFDAC GMP Regulations 2021 + NAFDAC Drug + Related Products Registration Regulations 2021 + NAFDAC Medical Devices Regulations + MAS scratch-code + WHO PQ CRP + ECOWAS-MRH readiness.

• NAFDAC GMP Regulations 2021 control framework — WHO TRS 986 Annex 2 + ICH Q7 + EU GMP-aligned controls (clean rooms, aseptic process, environmental monitoring, computerised systems) with ALCOA+ data-integrity + Nigerian-specific Regulations 2021 + NAFDAC-specific elements + Nigerian climate-zone IVb stability monitoring.
• NAFDAC drug-registration packaging — Nigerian CTD-aligned dossier structure with Nigerian Module 1 specifics + Nigerian-specific Module 3 stability + Nigerian PIL + Nigerian-English labelling + Nigerian Authorised Representative declarations.
• WHO PQ CRP workflow — CRP Recipient packaging with WHO PQ Assessment Report + NAFDAC-specific overlay + reduced dossier + accelerated 90-day review path.
• ECOWAS-MRH workflow — ECOWAS-MRH joint assessment + reliance pathway packaging for multi-country West African registration including Ghana + Côte d'Ivoire + Senegal + Mali + Burkina Faso.
• AMRH + AMA workflow — AU AMA + AUDA-NEPAD AMRH reliance pathway packaging for continental coverage.
• Nigerian Authorised Representative workflow — foreign-manufacturer NAR designation + role-management + Nigerian-specific post-market surveillance + NAFDAC interface.
• MAS scratch-code workflow — MAS scratch-code generation + secure under-panel printing + NAFDAC backend integration + Nigerian SMS verification + counterfeit-flagging response handling for MAS-mandatory product categories (ACTs + ARVs + selected antibiotics + maternal health medicines).
• Nigerian clinical-trial workflow — NAFDAC Good Clinical Practice + NHREC Ethics Committee + Nigerian Pharmacopoeia + Nigerian-population pharmacovigilance + NAFDAC CTA submission + Nigerian SUSAR reporting.
• NAFDAC Med-Safety pharmacovigilance — E2B(R3) ICSR generation + 15-day SUSAR timeline + PSUR / PBRER packaging + Nigerian-language ICSR + Nigerian-population focus + NAFDAC Med-Safety + NPC platform integration.
• Medical-device + cosmetic + nutraceutical workflow — NAFDAC Medical Devices Regulations + Cosmetic Products Regulations + Nutraceutical Regulations dossier packaging + Class I-IV + IVD classification + ISO 13485 + Nigerian Authorised Representative + post-market surveillance + materiovigilance.
• NAFDAC Variations workflow — Type IA / IB / II classification + NAFDAC procedure + Nigerian-language packaging.
• Renewal workflow — 5-year renewal window tracking + NAFDAC procedure packaging.
• ECOWAS + AU regional bridging — for companies operating across West Africa + Africa, V5 surfaces Nigerian + Ghanaian FDA + Ivorian + Senegalese + Malian + South African SAHPRA + Egyptian EDA + Kenyan PPB + Ugandan NDA + Rwandan FDA harmonised dossier-element reuse alongside national-specific extensions.